1 option
Abeta toxicity . Part 1 / Colin L. Masters.
- Format:
- Video
- Author/Creator:
- Masters, Colin L., speaker, author.
- Series:
- Henry Stewart talks. Biomedical & life sciences collection. Alzheimer's disease.
- Henry Stewart talks. Biomedical & life sciences collection. Drug discovery and development in the neurosciences.
- Alzheimer's disease : neurobiology, pathology and treatment, 2056-452X
- Drug discovery and development in the neurosciences, 2056-452X
- Language:
- English
- Subjects (All):
- Alzheimer's disease--Chemotherapy.
- Alzheimer's disease.
- Alzheimer's disease--Pathophysiology.
- Alzheimer's disease--Treatment.
- Amyloid beta-protein.
- Alzheimer Disease--drug therapy.
- Alzheimer Disease--physiopathology.
- Alzheimer Disease--therapy.
- Amyloid beta-Peptides--toxicity.
- Medical Subjects:
- Alzheimer Disease--drug therapy.
- Alzheimer Disease--physiopathology.
- Alzheimer Disease--therapy.
- Amyloid beta-Peptides--toxicity.
- Genre:
- Video recordings.
- Physical Description:
- 1 online resource (1 streaming video file (54 min.)) : color, sound.
- polychrome
- Other Title:
- Aβ toxicity, Part I Title from title frames
- Abeta toxicity, Part I
- Place of Publication:
- London : Henry Stewart Talks, 2011.
- System Details:
- Mode of access: World Wide Web.
- video file
- Contents:
- Contents: The amyloid plaque
- Impact of delaying onset of AD
- The amyloidocentric theory of Alzheimer's disease
- Compelling evidence for the Abeta theory of AD
- Delay onset of AD by 5 years
- The best target for a disease-modifying drug
- APP structure and domains
- Iron-export ferroxidase activity of beta-amyloid precursor protein
- Age at onset correlates with Abeta isoforms
- Activation of PS1
- Abeta amyloid
- The mechanism of neurodegeneration
- Abeta metal binding modes
- Current working model of Abeta toxicity
- Abeta amyloid protein: current model consistent with EXAFS
- Metal-protein attenuating compound (MPAC) with moderate affinity for metals
- Clioquinol (CQ, PBT1) the prototypic MPAC
- PBT2: SAR based on rational drug design
- CQ (PBT1) vs. PBT2
- Alzheimer's disease Abeta-directed therapeutics in clinical development: drugs and biologics
- Phase II results of Abeta targeting AD modifying drugs.
- Notes:
- Animated audio-visual presentation with synchronized narration.
- Title from publisher's website (viewed January 2012).
- Publisher Number:
- 2957 Henry Stewart Talks
- Access Restriction:
- Restricted for use by site license.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.